Abstract
Aim: Despite numerous available antiemetics, chemotherapyinduced nausea and vomiting (CINV) still affects many patients, and CINVrelated hospitalizations and costs often result. Materials & methods: PrecisionQ analyzed its database to evaluate CINVrelated hospitalizations and costs following antiemetics use including netupitant/fosnetupitant with palonosetron (NEPA), aprepitant/fosaprepitant with ondansetron (APON)or aprepitant/fosaprepitant with palonosetron (APPA) in patients receiving highly emetogenic chemotherapyor moderately emetogenic chemotherapy. Results: Database analysis identified 15,583 patient records (807 NEPA, 2023 APON, 12,753 APPA)and mean CINVrelated hospitalization costs were lower across all patients receiving NEPA (US$301) compared with patients receiving APON ($1006, p<0.0001) or APPA ($321, p<0.0001). Conclusion: NEPA is associated with lower CINVrelated hospitalization costs compared with APON and APPA among patients receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
